Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

TL;DR: The risk of intracerebral haemorrhage (ICH) is increased in patients with ischaemic cerebrovascular disease and vice versa and risk factors shared by both stroke subtypes, such as hypertension, age, and smoking, partly explain this observation.

TL;DR: The evidence for managing patients presenting with visual symptoms of vascular events is reviewed, and management of ischemic stroke in general is compared with management of events involving the anterior circulation by way of transient monocular visual loss or retinal artery occlusion, and posterior circulation byway of transient binocularVisual loss or infarction of the visual cortex.

TL;DR: Recommendations for clinical practice in prevention of ischemic stroke according to the aetiological subtype presented by the patient are concluded.

TL;DR: Interventional techniques aim at recanalization of the carotid artery for early restoration of cerebral blood flow and secondary prevention of future strokes in patients with a chronic occlusion of the contralateral ICA.

TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.

TL;DR: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.

TL;DR: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.

TL;DR: Following PCI, long-term clopidogrel therapy significantly reduced the risk of adverse ischemic events and subgroup analyses suggest that longer intervals between the loading dose and PCI may reduce events.